Ezra Cohen to Cost-Benefit Analysis
This is a "connection" page, showing publications Ezra Cohen has written about Cost-Benefit Analysis.
Connection Strength
0.121
-
Current treatment options for metastatic head and neck cancer. Curr Treat Options Oncol. 2012 Mar; 13(1):35-46.
Score: 0.085
-
Cost-effectiveness analysis of nivolumab for the treatment of squamous cell carcinoma of the head and neck in the United States. J Med Econ. 2020 May; 23(5):442-447.
Score: 0.037